Cytotoxic inhibitors of Hsp90 are the ONLY cancer chemotherapeutic agents known to impact all six hallmarks of cancer simultaneously. As defined by Hanahan and Weinberg, this includes:
1) self-sufficiency in growth signals,
2) insensitivity to antigrowth signals,
3) evasion of apoptosis,
4) limitless replicative potential,
5) sustained angiogenesis, and
6) tissue invasion/metastasis.
*This study indicated that LUTEOLIN may act as a potent HSP90 inhibitor in antitumor strategies.